FUJIFILM Diosynth Biotechnologies Enters Manufacturing Supply Agreement with TG Therapeutics
FUJIFILM Diosynth Biotechnologies, a global CDMO leader in for biologics, vaccines, advanced therapies, and oncolytic viruses, announced today that TG Therapeutics, Inc. has entered into a multi-year manufacturing supply agreement for BRIUMVI® (ublitiximab-xiiy), its U.S. FDA-approved treatment for relapsing forms of multiple sclerosis. As part of the agreement, FUJIFILM Diosynth will provide secondary U.S.-based manufacturing support for BRIUMVI at its new biopharmaceutical manufacturing facility in North Carolina, which is set to become operational in 2025.
FUJIFILM Diosynth Biotechnologies Enters Manufacturing Supply Agreement with TG Therapeutics